Michael Timothy Cooke
Chief Executive Officer at NovaDigm Therapeutics, Inc.
Profile
Michael Timothy Cooke is the founder of MSD Vaccines Ltd.
He currently holds the position of Chief Executive Officer & Director at NovaDigm Therapeutics, Inc. since 2013 and Chief Executive Officer at VaxNewMo LLC since 2022.
Previously, he served as Chief Executive Officer at Mojave Therapeutics, Inc. and Senior Director-Worldwide Marketing Planning at Merck Vaccine Division.
From 2004 to 2008, he was the Chief Operating Officer at AVANT Immunotherapeutics, Inc. In terms of education, he holds an MBA and a doctorate from The Trustees of Columbia University in The City of New York, and an undergraduate degree from St. Joseph's University.
Michael Timothy Cooke active positions
Companies | Position | Start |
---|---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Chief Executive Officer | 2009-01-31 |
VaxNewMo LLC
VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Chief Executive Officer | 2021-12-31 |
Former positions of Michael Timothy Cooke
Companies | Position | End |
---|---|---|
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Chief Operating Officer | 2008-02-10 |
Merck Vaccine Division | Corporate Officer/Principal | - |
MSD Vaccines Ltd.
MSD Vaccines Ltd. Pharmaceuticals: OtherHealth Technology MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom. | Founder | - |
Mojave Therapeutics, Inc. | Chief Executive Officer | - |
Training of Michael Timothy Cooke
The Trustees of Columbia University in The City of New York | Doctorate Degree |
St. Joseph's University | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
MSD Vaccines Ltd.
MSD Vaccines Ltd. Pharmaceuticals: OtherHealth Technology MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Mojave Therapeutics, Inc. | |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
Merck Vaccine Division | |
VaxNewMo LLC
VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Michael Timothy Cooke